Table 3.

Overview of new cases and relapses of Graves’ disease following SARS-CoV-2 vaccination reported in the literature.

	New Onset GD	GD Recurrence
Number of Cases	48	15
Sex	F (70.8%)—M (29.2%)	F (73.3%)—M (26.7%)
Age (years), median [IQR]	43 [IQR 35–50.5]	41 [IQR 30–59]
Type of SARS-Cov-2 vaccine	BNT162b2 50% ChAdOx1 27% mRNA-1273 8.3% Ad26.COV2.S 2.2% Not specified (mRNA) 12.5%	BNT162b2 33.3% ChAdOx1 + CoronaVac 6.6% Ad26.COV2.S 6.6% CoronaVac 6.6% mRNA-1273 6.6% Not specified (mRNA) 40%
Days to symptoms onset, median [IQR]	10 [IQR 5–14]	11 [IQR 6–28]
Major symptoms	palpitations (61.9%) weight loss (35.7%) distal tremor (28.6%) behavioral/sleep disorders (26.1%) asthenia (21.4%) GI symptoms (14.3%)	palpitations (77.8%) sweating (55.5%) weight loss (33.3%)
TSH (IU/mL), median [IQR]	0.008 [0.004–0.01]	0.01 [0.008–0.01]
fT3 (ng/L), median [IQR]	13.2 [9.83–19.9]	13.5 [7.97–22.45]
fT4 (ng/dL), median [IQR]	3.58 [254–5.34]	3.32 [1.55–3.86]
TRAb (IU/L), median [IQR]	6.45 [4.39–16-56]	5.8 [3.85–13.4]

Abbreviations: GD, Graves’ disease; SARS-CoV-2, severe acute respiratory syndrome coronavirus 2; IQR, interquartile range; GI, gastrointestinal; TSH, thyrotropin; fT3, free triiodothyronine; fT4, free tiroxine; TRAb, TSH receptor antibody.